Monday, January 30, 2012

Vemurafenib Seeks Wider Audience

Vemurafenib (Zelboraf ®; Genentech/Daiichi Sankyo) is a BRAF V600E kinase inhibitor approved for metastatic melanoma.  Since its approval last year, vemurafenib has become the drug of choice for these patients.  BRAF V600E mutant gene is also found in several other solid cancer, including colon, ovarian and thyroid, and certain leukemias.  Zelboraf is making inroads in these cancer types.

Read the complete article "Vemurafenib for Melanoma and Other Cancers" at Chemotherapy Advisor.


Malik A. Vemurafenib for Melanoma and Other Cancers. Chemotherapy Advisor. January 25, 2012.  Accessed January 30, 2012.

(Find this article at InternetArchive here)

Related Posts:

OncoBrands We Used to Know in 2011. December 31, 2011.
Can we check off thyroid cancer as a conquered disease? Maybe not! October 16, 2010 

To Re-tweet this article, click here.

No comments:

Post a Comment